Drug Discovery

Bayer gets full rights to Vitrakvi, LOXO-195 from Lilly’s Loxo Oncology

Bayer has obtained the full rights to global development and commercialization of Vitrakvi (larotrectinib) and BAY 2731954 (LOXO-195) from the US-based Loxo Oncology.

SK, Arvelle sign $530m deal for antiepileptic drug cenobamate

SK Biopharmaceuticals has entered into a $530m deal with the Arvelle Therapeutics for investigational antiepileptic drug cenobamate.

Vor Biopharma raises $42m to advance development of cell therapy product candidate for AML

Vor Biopharma, an immuno-oncology company pioneering engineered hematopoietic stem cell (HSC) therapies for the treatment of hematological malignancies, has announced a $42m Series A financing round led by 5AM Ventures and RA Capital Management.

Redx says in vivo data indicates potential of ROCK2 in fibrosis treatment

UK based biotech company Redx said that its lead selective ROCK2 compound has been shown to have broad potential in the treatment of fibrosis as per new in vivo data.

AbbVie, Teneobio sign deal to develop new treatment for multiple myeloma

AbbVie, Teneobio, and its affiliate TeneoOne have entered a global strategic transaction to develop and commercialize TNB-383B, a BCMA-targeting immunotherapeutic for the potential treatment of multiple myeloma.

Samsung Bioepis, C-Bridge Capital to develop and commercialize next-generation biosimilars in China

Samsung Bioepis has announced its expansion in mainland China through a licensing agreement with C-Bridge Capital.

Evotec, Galapagos enter into collaboration in fibrosis field

Evotec and Galapagos have announced a global collaboration focused on a novel target for fibrosis and other indications.

Ligand announces OmniAb partnership with Genagon Therapeutics

Ligand Pharmaceuticals has entered into a worldwide OmniAb partnership with Genagon Therapeutics AB, an immuno-oncology focused biotech located in Sweden.

TamRx launches to develop pipeline of immuno-oncology products for treatment of cancers

BioMotiv, a drug development accelerator associated with The Harrington Project for Discovery & Development, and researchers from Rutgers, The State University of New Jersey, announced the formation of a new biotech start-up, TamRx.